Nature Cardiovascular Research, published by SpringerNature in Germany, stands as a premier journal dedicated to advancing the field of cardiovascular sciences. With an impressive 2023 categorization in the Q1 quartile across multiple disciplines—including Biochemistry, Genetics and Molecular Biology, Cardiology, and Medicine—this journal uniquely positions itself as a leading resource for pioneering research and innovative findings. Although currently not open access, it provides a rich repository of peer-reviewed articles that contribute directly to the evolving landscape of cardiovascular medicine. The journal aims to bridge the knowledge gap between basic science and clinical application, catering to researchers, healthcare professionals, and students alike who are immersed in the complexities of cardiovascular health. With robust Scopus rankings in key categories, Nature Cardiovascular Research is poised to shape future directions in the field, helping to foster a deeper understanding of cardiovascular diseases and their underlying mechanisms. Explore the latest research and be part of the conversation in one of the most impactful scientific domains.

Cardiogenetics, published by MDPI, is a leading open-access journal dedicated to advancing the field of genetics as it pertains to cardiovascular health and diseases. Since its launch in 2011, this journal has been at the forefront of disseminating high-quality research that explores the genetic underpinnings of cardiovascular conditions, offering a platform for innovative studies, reviews, and case reports. With an ISSN of 2035-8253 and an E-ISSN of 2035-8148, Cardiogenetics aims to bridge the gap between genetic research and clinical application, helping researchers, healthcare professionals, and students stay abreast of the latest advancements and findings. The journal’s commitment to open access ensures that its valuable content is available to a global audience, fostering greater collaboration and knowledge sharing in the cardiovascular genetics community. By contributing to this dynamic field, Cardiogenetics plays a crucial role in improving patient outcomes and paving the way for personalized medicine in cardiology.

GENETICS, published by the Genetics Society of America, stands as a preeminent journal in the field of genetics, with a keen focus on advancing the understanding of genetic principles and their implications across various biological systems. Since its inception in 1945, the journal has played a pivotal role in disseminating groundbreaking research, maintaining a Q1 ranking in the genetics category as of 2023, positioning it among the top tier of academic publications. While access to the journal is not open, it continues to attract a global readership of researchers, professionals, and students eager to engage with high-quality, peer-reviewed articles that span both classical and contemporary genetics. With its publication history covering critical decades from 1945 to 2024, GENETICS is not just a repository of scientific knowledge but a vibrant forum for the exchange of ideas that drive the field forward. The journal’s commitment to excellence is demonstrated by its strategic coverage of pertinent topics, assuring its relevance for future generations of scholars.

Netherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.

Current Genetic Medicine Reports, published by SPRINGERNATURE, is a prominent journal dedicated to advancing the field of genetic medicine. With an emphasis on the latest research and advancements, this journal serves as a critical platform for disseminating high-quality original articles, reviews, and reports that focus on the application of genetic information in various medical disciplines. As an open-access journal, it ensures that valuable findings are freely accessible to a global audience, thereby fostering collaboration and innovation among researchers, healthcare professionals, and students alike. Although the journal does not yet have an established impact factor, its commitment to rigorous peer review and its contributions to the understanding and integration of genetic medicine into clinical practice enhance its scholarly significance. The editorial board is comprised of leading experts, encouraging submissions that tackle contemporary issues in genetic research and its clinical applications. Located in London, England, this journal is poised to be a vital resource for those seeking to stay abreast of the rapid changes in the dynamic field of genetic medicine.

CARDIOLOGY, published by KARGER, is a renowned scholarly journal dedicated to the advancement of research in the fields of cardiology and cardiovascular medicine. Since its inception in 1937, the journal has consistently provided a platform for high-quality, peer-reviewed articles that contribute to the understanding and treatment of heart and vascular diseases. With an impressive convergence through 2024, CARDIOLOGY holds a respectable Q2 ranking in both the Cardiology and Cardiovascular Medicine and Pharmacology (medical) categories, placing it within the 53rd and 45th percentiles of respective Scopus ranks. Based in Switzerland, the journal serves as an essential resource for researchers and practitioners aiming to stay abreast of cutting-edge developments and evidence-based practices in cardiovascular health. While it currently does not offer open access options, its commitment to rigorous scientific standards solidifies its significance within the academic community. We invite readers to explore the latest research findings and contribute to this vital field through publications in CARDIOLOGY.

Byulleten Sibirskoy Meditsiny, published by the Siberian State Medical University, is a pivotal open-access journal in the field of Molecular Medicine, with its current edition indexed under the ISSN 1682-0363. Since its transition to open access in 2013, the journal aims to disseminate high-quality research and advancements in biomedical sciences, particularly focusing on molecular mechanisms and therapeutic interventions. Despite its relatively recent recognition in Molecular Medicine, where it ranks in the 6th percentile, the journal is dedicated to fostering knowledge exchange and collaboration among researchers, professionals, and students alike. With a modest impact factor and quarterly publication, Byulleten Sibirskoy Meditsiny is positioned to serve as a valuable resource for those engaged in the intricate realms of molecular biology, biochemistry, and general medicine, contributing to the broader scientific discourse in the Russian Federation and beyond.

Annual Review of Pathology: Mechanisms of Disease is a premier scholarly journal published by ANNUAL REVIEWS that systematically reviews significant advancements in the field of pathology and the mechanisms underpinning various diseases. With an ISSN of 1553-4006 and an E-ISSN of 1553-4014, the journal has established its importance within the academic community, evidenced by its prestigious Q1 rankings in several categories including medicine, pathology, forensic medicine, and plant science for 2023. Notably, it ranks #1 out of 208 in the pathology and forensic medicine category, placing it in the 99th percentile according to Scopus metrics. Although not an open-access journal, it offers crucial insights to researchers, professionals, and students alike by providing a comprehensive understanding of pathophysiological concepts and emerging trends. The journal continues to be an essential resource for those dedicated to advancing research and practical applications in disease mechanisms.

Indian Heart Journal, published by Elsevier, is a distinguished peer-reviewed journal dedicated to the field of cardiology and cardiovascular medicine. Founded in 1961, this journal has been a pivotal resource for researchers, healthcare professionals, and students, providing a platform for innovative studies and insights into heart health. The journal transitioned to an Open Access model in 2013, ensuring widespread dissemination of vital research findings to enhance global understanding of cardiovascular diseases. Ranked in the Q3 category for Cardiology and Cardiovascular Medicine in 2023, it holds a reputable position in the medical community, with a Scopus rank of #222 out of 387 journals in the same field, placing it in the 42nd percentile. The Indian Heart Journal strives to foster advances in clinical practice and research while addressing the unique cardiac health challenges faced in India and beyond.

Expert Review of Precision Medicine and Drug Development, published by Taylor & Francis Ltd, is a valuable academic resource that thrives at the intersection of pharmacology, genetics, and molecular medicine. Since its inception in 2016, this journal has rapidly become a pivotal platform for researchers and practitioners aiming to advance the field of drug development through innovative precision medicine strategies. With a broad focus encompassing the latest advancements in drug discovery and genetic research, it operates within a competitive landscape, evidenced by its recent category quartile rankings where it holds Q4 in Drug Discovery, Genetics, and Molecular Medicine, alongside a Q3 ranking in Pharmacology for the year 2023. The journal offers a unique opportunity for scholars to share insights and foster collaborations that can lead to breakthroughs in therapeutic approaches. Although not an open-access journal, it maintains a commitment to disseminating outstanding research to a wide audience. By fostering a rigorous peer-review process, the journal aims to enhance the quality and impact of publications within these critical areas of medicine, making it an essential read for anyone involved in healthcare and pharmaceutical advancements.